CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade vTv Therapeutics Inc. - VTVT CFD

0.94
0%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.07
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.030779 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.030779%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.013666 %
Charges from borrowed part ($-0.55)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.013666%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 0.94
Open* 0.96
1-Year Change* 37.14%
Day's Range* 0.93 - 0.96
52 wk Range 0.38-1.40
Average Volume (10 days) 82.89K
Average Volume (3 months) 1.42M
Market Cap 102.09M
P/E Ratio -100.00K
Shares Outstanding 104.58M
Revenue 2.02M
EPS -0.31
Dividend (Yield %) N/A
Beta -1.09
Next Earnings Date Mar 27, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jan 27, 2023 0.94 -0.02 -2.08% 0.96 0.96 0.93
Jan 26, 2023 0.94 0.00 0.00% 0.94 0.96 0.88
Jan 25, 2023 0.95 -0.01 -1.04% 0.96 0.96 0.93
Jan 24, 2023 0.96 0.01 1.05% 0.95 0.97 0.94
Jan 23, 2023 0.98 -0.01 -1.01% 0.99 1.01 0.98
Jan 20, 2023 0.98 0.02 2.08% 0.96 1.01 0.95
Jan 19, 2023 0.95 0.05 5.56% 0.90 0.96 0.90
Jan 18, 2023 0.89 0.05 5.95% 0.84 0.90 0.84
Jan 17, 2023 0.85 0.03 3.66% 0.82 0.87 0.80
Jan 13, 2023 0.79 0.02 2.60% 0.77 0.82 0.77
Jan 12, 2023 0.78 0.02 2.63% 0.76 0.79 0.75
Jan 11, 2023 0.78 0.00 0.00% 0.78 0.80 0.77
Jan 10, 2023 0.77 0.00 0.00% 0.77 0.78 0.75
Jan 9, 2023 0.75 -0.03 -3.85% 0.78 0.80 0.74
Jan 6, 2023 0.75 0.01 1.35% 0.74 0.75 0.73
Jan 5, 2023 0.72 -0.03 -4.00% 0.75 0.75 0.71
Jan 4, 2023 0.74 0.07 10.45% 0.67 0.76 0.66
Jan 3, 2023 0.67 0.04 6.35% 0.63 0.70 0.63
Dec 30, 2022 0.64 0.00 0.00% 0.64 0.66 0.62
Dec 29, 2022 0.64 0.01 1.59% 0.63 0.65 0.63

vTv Therapeutics Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 0.634 0.291 12.434 2.764 6.414 4.005
Revenue 0.634 0.291 12.434 2.764 6.414 4.005
Total Operating Expense 55.654 50.973 32.258 23.656 18.266 25.667
Selling/General/Admin. Expenses, Total 9.906 11.333 9.223 8.537 7.251 11.443
Research & Development 45.748 39.64 23.035 15.119 11.015 12.624
Operating Income -55.02 -50.682 -19.824 -20.892 -11.852 -21.662
Interest Income (Expense), Net Non-Operating -0.311 -2.975 -3.229 -1.774 -0.68 -0.011
Other, Net -0.022 -0.19 -0.592 0.828 -0.27 4.057
Net Income Before Taxes -55.353 -53.847 -23.645 -21.838 -12.802 -17.616
Net Income After Taxes -55.353 -48.8 -23.845 -21.938 -12.802 -17.731
Minority Interest 39.001 38.503 15.934 8.894 4.303 4.744
Net Income Before Extra. Items -16.352 -10.297 -7.911 -13.044 -8.499 -12.987
Net Income -16.352 -16.144 -7.911 -13.044 -8.499 -12.987
Income Available to Common Excl. Extra. Items -16.352 -10.297 -8.65 -17.913 -8.499 -12.987
Income Available to Common Incl. Extra. Items -16.352 -16.144 -8.65 -17.913 -8.499 -12.987
Diluted Net Income -16.352 -16.144 -8.65 -17.913 -8.499 -12.987
Diluted Weighted Average Shares 9.54553 9.69325 12.4492 30.292 47.1379 60.7326
Diluted EPS Excluding Extraordinary Items -1.71305 -1.06229 -0.69482 -0.59134 -0.1803 -0.21384
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -1.71305 -1.06229 -0.69482 -0.59134 -0.1803 -0.19671
Total Extraordinary Items -5.847
Total Adjustments to Net Income -0.739 -4.869 0
Unusual Expense (Income) 1.6
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 0.987 0.009 3 0.009 2
Revenue 0.987 0.009 3 0.009 2
Total Operating Expense 5.267 4.679 4.603 11.118 8.481
Selling/General/Admin. Expenses, Total 2.164 2.242 2.221 5.716 5.348
Research & Development 3.103 2.437 2.382 5.402 3.133
Operating Income -4.28 -4.67 -1.603 -11.109 -6.481
Interest Income (Expense), Net Non-Operating 0.001 0 -0.006 -0.006 -0.001
Other, Net -1.648 3.829 0.244 1.632 -2.742
Net Income Before Taxes -5.927 -0.841 -1.365 -9.483 -9.224
Net Income After Taxes -5.942 -0.841 -1.465 -9.483 -9.424
Minority Interest 1.701 0.233 0.378 2.432 2.417
Net Income Before Extra. Items -4.241 -0.608 -1.087 -7.051 -7.007
Net Income -4.241 -0.608 -1.087 -7.051 -7.007
Income Available to Common Excl. Extra. Items -4.241 -0.608 -1.087 -7.051 -7.007
Income Available to Common Incl. Extra. Items -4.241 -0.608 -1.087 -7.051 -7.007
Diluted Net Income -4.241 -0.608 -1.087 -7.051 -7.007
Diluted Weighted Average Shares 56.4725 58.6151 61.0733 66.719 66.9428
Diluted EPS Excluding Extraordinary Items -0.0751 -0.01037 -0.0178 -0.10568 -0.10467
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.0751 -0.01037 -0.0178 -0.10568 -0.10467
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 52.117 20.362 3.473 2.838 7.215 15.621
Cash and Short Term Investments 51.505 11.758 1.683 1.777 5.747 13.415
Cash & Equivalents 51.505 11.758 1.683 1.777 5.747 13.415
Total Receivables, Net 0 8 0 0.005 0.158 0.057
Accounts Receivable - Trade, Net 0 8 0 0.005 0.158 0.057
Prepaid Expenses 0.612 0.442 0.666 0.806 0.939 1.914
Total Assets 54.495 27.917 8.559 9.266 14.789 25.474
Property/Plant/Equipment, Total - Net 0.444 0.283 0.07 1.004 0.849 0.68
Property/Plant/Equipment, Total - Gross 10.898 9.399 8.501 1.152 1.065 0.985
Accumulated Depreciation, Total -10.454 -9.116 -8.431 -0.148 -0.216 -0.305
Other Long Term Assets, Total 1.934 4.792 2.536 2.944 0
Total Current Liabilities 11.434 26.929 18.837 13.381 6.39 8.498
Accounts Payable 3.06 2.269 2.899 2.232 1.925 1.876
Payable/Accrued 0
Accrued Expenses 8.353 11.632 4.803 4.946 4.35 6.331
Notes Payable/Short Term Debt 0 0 0 0 0 0
Other Current Liabilities, Total 0.021 8.757 1.752 0.031 0.031 0.035
Total Liabilities 145.44 178.964 91.412 58.289 94.891 35.214
Total Long Term Debt 11.058 15.316 6.33 0 0 0
Long Term Debt 11.058 15.316 6.33 0
Minority Interest 122.515 131.44 62.482 40.183 83.895 24.962
Other Liabilities, Total 0.433 5.279 3.763 4.725 4.606 1.754
Total Equity -90.945 -151.047 -82.853 -49.023 -80.102 -9.74
Common Stock 0.329 0.329 0.435 0.641 0.773 0.901
Additional Paid-In Capital 124.212 127.682 150.595 183.858 209.161 238.193
Retained Earnings (Accumulated Deficit) -215.486 -279.058 -233.883 -233.522 -290.036 -248.834
Total Liabilities & Shareholders’ Equity 54.495 27.917 8.559 9.266 14.789 25.474
Total Common Shares Outstanding 32.8125 32.8125 43.4413 64.0127 77.1449 90.0366
Other Current Assets, Total 0.162 1.124 0.25 0.371 0.235
Long Term Investments 2.48 2.48 2.48 6.725 9.173
Current Port. of LT Debt/Capital Leases 4.271 9.383 6.172 0.084 0.256
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 9.221 11.272 22.171 15.621 13.612
Cash and Short Term Investments 8.449 10.835 19.566 13.415 12.138
Cash & Equivalents 8.449 10.835 19.566 13.415 12.138
Total Receivables, Net 0.002 0 0.928 0.057 0.057
Accounts Receivable - Trade, Net 0.002 0 0.928 0.057 0.057
Prepaid Expenses 0.71 0.313 1.574 2.049 1.387
Other Current Assets, Total 0.06 0.124 0.103 0.1 0.03
Total Assets 16.754 21.66 31.434 25.474 20.185
Property/Plant/Equipment, Total - Net 0.808 0.766 0.724 0.68 0.634
Long Term Investments 6.725 9.622 8.539 9.173 5.939
Total Current Liabilities 5.162 5.059 5.51 8.498 12.7
Payable/Accrued 4.965 4.855 4.663 8.023 12.474
Accrued Expenses 0.162 0.169 0.176 0.184 0.191
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 0 0.636 0.256 0
Other Current Liabilities, Total 0.035 0.035 0.035 0.035 0.035
Total Liabilities 73.029 69.483 52.979 35.214 28.278
Total Long Term Debt 0 0 0 0 0
Minority Interest 62.647 60.19 44.61 24.962 14.367
Other Liabilities, Total 5.22 4.234 2.859 1.754 1.211
Total Equity -56.275 -47.823 -21.545 -9.74 -8.093
Common Stock 0.808 0.834 0.897 0.901 0.901
Additional Paid-In Capital 217.647 224.457 236.557 238.193 238.669
Retained Earnings (Accumulated Deficit) -274.73 -273.114 -258.999 -248.834 -247.663
Total Liabilities & Shareholders’ Equity 16.754 21.66 31.434 25.474 20.185
Total Common Shares Outstanding 80.6658 83.2878 89.565 90.0366 90.0366
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line -55.353 -54.647 -23.845 -21.938 -12.802 -17.731
Cash From Operating Activities -48.209 -44.56 -26.856 -23.018 -18 -19.308
Cash From Operating Activities 0.265 0.197 0.218 0.039 0.094 0.089
Non-Cash Items 2.793 4.853 4.316 0.935 -2.586 -1.701
Cash Interest Paid 0.242 2.064 2.276 1.295 0.623 0.011
Changes in Working Capital 4.086 5.037 -7.545 -2.054 -2.706 0.035
Cash From Investing Activities -0.083 -0.025 0.007 0.242 0 0
Capital Expenditures -0.087 -0.057 -0.005 -0.07 0 0
Other Investing Cash Flow Items, Total 0.004 0.032 0.012 0.312 0 0
Cash From Financing Activities 11.794 7.5 16.612 22.87 19.47 26.976
Financing Cash Flow Items -0.673 0 0
Issuance (Retirement) of Stock, Net 0 0 21.5 32.943 24.426 26.804
Issuance (Retirement) of Debt, Net 12.467 7.5 -4.888 -10.073 -4.956 0.172
Net Change in Cash -36.498 -37.085 -10.237 0.094 1.47 7.668
Cash Taxes Paid 1 0.1 0 0.115
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -5.942 -6.783 -8.248 -17.731 -9.424
Cash From Operating Activities -5.299 -9.297 -12.891 -19.308 -1.021
Cash From Operating Activities 0.023 0.045 0.067 0.089 0.023
Non-Cash Items 2.084 -1.292 -1.063 -1.701 3.218
Changes in Working Capital -1.464 -1.267 -3.647 0.035 5.162
Cash From Financing Activities 8.001 14.385 26.71 26.976 -0.256
Issuance (Retirement) of Stock, Net 8.085 14.469 26.158 26.804 0
Issuance (Retirement) of Debt, Net -0.084 -0.084 0.552 0.172 -0.256
Net Change in Cash 2.702 5.088 13.819 7.668 -1.277
Cash From Investing Activities 0
Capital Expenditures 0
Other Investing Cash Flow Items, Total 0
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
MacAndrews & Forbes Holdings, Inc. Holding Company 44.9246 36606212 87000 2022-05-31 LOW
G42 Investments AI Holdings RSC, Ltd. Corporation 12.7465 10386274 10386274 2022-05-31 LOW
Medpace Investors, L.L.C. Corporation 6.6241 5397529 5397529 2022-08-16 LOW
Samsara BioCapital, LLC Venture Capital 2.0072 1635509 0 2022-09-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 1.1523 938970 0 2022-09-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.3559 290000 -76618 2022-09-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.1654 134745 -71400 2022-09-30 LOW
Millennium Management LLC Hedge Fund 0.0949 77339 -61344 2022-09-30 HIGH
Fry (John Anthony) Individual Investor 0.0749 61000 61000 2022-11-29 LOW
Nelson (Rich S) Individual Investor 0.0736 60000 0 2022-04-04
BlackRock Institutional Trust Company, N.A. Investment Advisor 0.0661 53845 -287 2022-09-30 LOW
Virtu Americas LLC Research Firm 0.0539 43954 5395 2022-09-30 HIGH
Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.0498 40577 0 2022-09-30 LOW
PGIM Quantitative Solutions LLC Investment Advisor 0.0491 40000 0 2022-09-30 LOW
Morgan Stanley Smith Barney LLC Investment Advisor 0.041 33442 0 2022-09-30 LOW
Citadel Advisors LLC Hedge Fund 0.0405 33012 -4256 2022-09-30 HIGH
Two Sigma Investments, LP Hedge Fund 0.0397 32385 14590 2022-09-30 HIGH
Simon Quick Advisors, LLC Investment Advisor 0.0368 30000 0 2022-09-30 MED
Bridgeway Capital Management, LLC Investment Advisor 0.0332 27018 27018 2022-09-30 LOW
Kozlov (Hersh) Individual Investor 0.0307 25000 0 2022-04-04

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
+485000+

Traders

65000+

Active clients monthly

$48000000+

Monthly investing volume

$28000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

vTv Therapeutics Inc. Company profile

About vTv Therapeutics Inc

vTv Therapeutics Inc. is a clinical-stage pharmaceutical company that is engaged in the discovery and development of orally administered small molecule drug candidates. It is developing a program for the treatment of type I diabetes TTP399 and for psoriasis HPP737. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. The Company is also conducting a multiple ascending dose Phase I study of HPP737, an orally administered phosphodiesterase type IV inhibitor, to assess the pharmacokinetics, pharmacodynamics, safety and tolerability of HPP737 in healthy volunteers as part of its psoriasis program. Its TTP273 is an oral, small molecule, glucagon-like peptide I (GLP-1) receptor agonist being evaluated for the treatment of type II diabetes mellitus.

Financial summary

BRIEF: For the nine months ended 30 September 2021, vTv Therapeutics Inc revenues increased from $15K to $4M. Net loss decreased 38% to $5.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Other (expense) income increase from $0K to $1.8M (income), Research and Development - Balancing decrease of 10% to $7.4M (expense).

Industry: Bio Therapeutic Drugs

3980 Premier Dr
Suite 310
HIGH POINT
NORTH CAROLINA 27265
US

Income Statement

  • Annual
  • Quarterly

People also watch

BTC/USD

23,076.55 Price
-0.220% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 60.00

XRP/USD

0.41 Price
-0.590% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 0.00331

US100

12,164.80 Price
+1.340% 1D Chg, %
Long position overnight fee -0.0179%
Short position overnight fee 0.0070%
Overnight fee time 22:00 (UTC)
Spread 3.0

Natural Gas

2.86 Price
+0.740% 1D Chg, %
Long position overnight fee -0.0485%
Short position overnight fee 0.0282%
Overnight fee time 22:00 (UTC)
Spread 0.005

Still looking for a broker you can trust?

Join the 480.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading